Tag: Ulcerative Colitis

Prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease is about 2 percent

In 60 percent of patients, IUS had impact on disease management, with change in medication in 47.8 percent

Cyltezo is first interchangeable monoclonal antibody for RA, psoriatic arthritis, ankylosing spondylitis, Crohn disease, ulcerative colitis, chronic plaque psoriasis

Once-daily oral ozanimod more effective than placebo for moderately to severely active ulcerative colitis

Fecal transplant with or without dietary intervention less successful than dietary intervention alone in generating clinical remission

Global prevalence of primary sclerosing cholangitis ranges from 0.96 percent in Crohn disease to 2.47 percent in ulcerative colitis

New index shows strong correlation with endoscopically determined disease activity

Increase higher among non-Hispanic Blacks, while prevalence was consistently highest for non-Hispanic Whites